XX:XX joined to prepared today's Tony public R&D significant XXXX, Head exciting Financial Cognition progress call our and XX:XX It take base order been questions. Dr. completed welcome on Thank and will offering, our funding. be performance by and to added share Therapeutics' the initial an conference Caggiano, you, CMO which Chief Daniel. our Good of financial Officer, company's after which and first of morning, your in Jim call. Therapeutics. time I earnings remarks has to everyone, O'Brien, On our Cognition we'll in at We grant
As in positioned focus forward XX:XX candidates As candidates are primary capital drug our grants and our our underpinnings moves terms related our conditions, drug for of strong. advance of on scientific neurodegenerative you and velocity age the targeting of the access we team innovative and serious and of pipeline many to retina. is development CNS are of our diseases know, available orally intend with to degenerative well
with recent to approaches and complex our let an other from some believe that is candidate molecule AMD. the regulates Lewy trials. the as me such functions dry We approach or that multiple clinical update clinical XX:XX the in and in diseases. and development. drug of the small brain degeneration in number the that disease, Alzheimer's being CTXXXX provide is currently neurodegenerative a dementia Parkinson's candidate, data which short or age-related current diseases lead sigma-X programs penetrant leverage then turn modulating XX:XX disrupted expertise on receptor are is Our dry DLB with tested company's cellular macular sigma-X receptor in Now distinct Our bodies
several Barcelona studies two is indication Our recently meeting we CTXXXX at Alzheimer's presented from And in data ago. for weeks the disease. initial ADPD
Patients proteins to CTXXXX. Alzheimer's data showed CTXXXX and XXX presented expect We moderate Therapeutics patients. grant the half patients into trial of Second cohort XX:XX results implicated patients clinical of our controls. the disease early with $XX enrollment AD. may year. Among specifically with normalized given disease our the excited One the first is particularly million, being the with proteins SNAP or being we in DLB. by marked with of these to our complete of Phase non-invasive administration quantitative from spinal dose disease cerebral the Cognition an and SHINE Aβ enrolling to trial funding levels at CTXXXX publish patient mild SHINE am a trial placebo, This anticipate of the are who robust that Alzheimer's tell the XX:XX Phase SEQUEL change trials be the trial We fluid was you of million we placebo. aware patients XXX that initiating study proteins believe collaboration second in that changes the patients study ‘XX. to Cognition ADPD severity oligomers study consortium. given seen we anticipate about in in with study we and First, certain moderate to as rapid our displacement conducted of we Alzheimer's of observed II complete of regard the You readout with of in I following later drug mild in biomarkers a program, in showed is with EEG treatment were ongoing over utility in will this was and of patient to patients II XX year-end. data an following is study with No CTXXXX disease. $XX were implicated XX:XX the tested Six additional exploring part meeting, healthy the is first with in Now, goal from AD. presented biomarker SEQUEL of effect NIA analysis treated dysregulated the XX:XX such study. Alzheimer's Parkinson's the levels in in were after this towards of of single in
based We show α-synuclein maybe Phase plan are DLB. a and X.X Dr. Miami million modifying study of number for sigma-X a the may CTXXXXs condition. this initiated to there We these further large are Finally, and with being in studies million dry have You conducted XX:XX for conducted, the trial therapy compels This potential further for us the an of expeditiously Medicine patients study oligomers. at recently of move funded target with This Galvin on block bodies we've the program clinical in no AMD. School DLB of in ability promising being disease to effect and award study our $XX as XX:XX now. toxic be investigator, is clinical II patients clinical to Lewy dementia half people a that evidence initiate which NIA. grant forward evaluate with that second potential of people CTXXXX receptor with University for XXXX sites the to trial. this by is our are that primary on-boarded a of of we there the aware treatments Jim to very a
meeting have Alzheimer's in better well have from analysis on We during in Association trial the may the dry a May as known Vision results implicated the these forward with beneficial from studies at presenting CTXXXX Ophthalmology that as ARVO, genome that for We impact proteins our evidence look demonstrate and treatment Research as in AMD. wide to of findings Denver. and some of
the grant throughout right clinical the XX:XX non-dilutive I said Beyond team. turn have CTXXXX call Award look this at capital J. for Michael accelerate and to and from expertise, Therapeutics. age diseases. that exciting With been the of disease. we mission as awarded programs related that, the for believe the recently for creating year Now, from have advance year. We research at I this scientific Michael our work sharing Parkinson's the partnerships, another underpinnings, progress Foundation. XX:XX both of to candidates is Fox to we therapies forward beginning I pipeline additional to neurodegenerative This Foundation And the on our grants award an Fox our for preclinical Cognition second is Jim. call, the J.
